Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1

Acta Ophthalmologica

Volumn 90, Issue 7, 2012, Pages

  Zheng, Ying ^a   Gu, Qing ^a   Xu, Xun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

angiogenesis; inhibitor; peptide; placenta growth factor 1

Indexed keywords

ANGIOGENESIS INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN; PEPTIDE ZY1; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; ELECTROPHYSIOLOGY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOLOGY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA NEOVASCULARIZATION; RETINOPATHY; RHESUS MONKEY; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MACACA MULATTA; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEIN V-AKT; OXYGEN; PEPTIDE FRAGMENTS; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84868210627     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02476.x     Document Type: Article

References (38)

1. Antosova Z, Mackova M, Kral V, &, Macek T, (2009): Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 27: 628-635.
2. Bajou K, Masson V, Gerard RD, et al., (2001): The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777-784. (Pubitemid 34280162)
3. Carmeliet P, &, Jain RK, (2000): Angiogenesis in cancer and other diseases. Nature 407: 249-257.
4. Carneiro A, Falcao M, Pirraco A, et al., (2009): Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 88: 522-527.
5. Christinger HW, Fuh G, de Vos AM, &, Wiesmann C, (2004): The crystal structure of placental growth facotr in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem 279: 10382-10388. (Pubitemid 38372646)
6. Das A, &, McGuire PG, (2003): Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22: 721-748. (Pubitemid 37298046)
7. Errico M, Riccioni T, Iyer S, et al., (2004): Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem 279: 43929-43939. (Pubitemid 39390701)
8. Fischer C, Jonckx B, Mazzone M, et al., (2007): Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475. (Pubitemid 350007692)
9. Folkman J, (2006): Angiogenesis. Annu Rev Med 57: 1-18. (Pubitemid 43261975)
10. Giantonio BJ, Levy DE, O'Dwyer PJ, et al., (2006): A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 17: 1399-1403. (Pubitemid 44400378)
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al., (2004): Pegaptanib for neovascular age-related macular degeneration. VEGF inhibition study in Ocular Neovascularization Clinical Trial Group. N Engl J Med 351: 2805-2816.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al., (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
13. International Standardization Committee (1989). Standard for clinical electroretinography. Arch Ophthalmol. 107: 816-819.
14. Inan UU, Avci B, Kusbeci T, et al., (2007): Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773-1781. (Pubitemid 351261365)
15. Iyer S, Leonidas DD, Swaminathan J, et al., (2001): The crystal structure of human placenta growth factor-1 (PlGF-1) an angiogenic protein at 2.0 Ã resolution. J Biol Chem 276: 12153-12161.
16. Kamei M, Misono K, &, Lewis H, (1999): A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 128: 739-746. (Pubitemid 30001770)
17. Kasai A, Shintani N, Oda M, et al., (2004): Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 325: 395-400. (Pubitemid 39458008)
18. Kwan AS, Vijayasekaran S, McAllister IL, et al., (2006): A study of retinal penetration of intravitreal tenecteplase in pigs. Invest Ophthalmol Vis Sci 47: 2662-2667. (Pubitemid 351639855)
19. Lee P, Wang CC, &, Adamis AP, (1998): Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43: 245-269. (Pubitemid 28558273)
20. Lien S, &, Lowman HB, (2003): Therapeutic peptides. Trends Biotechnol 21: 556-562. (Pubitemid 37415008)
21. Luttun A, Autiero M, Tjwa M, &, Carmeliet P, (2004): Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta 1654: 79-94. (Pubitemid 38230933)
22. Maglione D, Guerriero V, Viglietto G, et al., (1991): Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88: 9267-9271. (Pubitemid 21915612)
23. Marmor MF, Holder GE, Seeliger MW, et a1. (2004): Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108: 107-114 (Pubitemid 39140118)
24. Nguyen QD, Brown DM, Marcus DM, et al., (2012): Ranibizumab for diabetic macular edema results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology 119: 789-801.
25. Patel RD, Momi RS, Hariprasad SM, et al., (2011): Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol 26: 372-379.
26. Ribatti D, (2008): The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 11: 215-221.
27. Rüegg C, Hasmim M, Lejeune FJ, &, Alghisi GC, (2006): Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta 1765: 155-177. (Pubitemid 44294394)
28. Shen HL, &, Chen HP, (2008): Effect of extracellular signal-regulated kinase pathway on nitric oxide release by human umbilical vein endothelial cell induced by placental growth factor-1. Zhonghua Fu Chan Ke Za Zhi 43: 410-413.
29. Sulochana KN, &, Ge R, (2007): Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 13: 2074-2086. (Pubitemid 47040489)
30. Tjwa M, Luttun A, Autiero M, &, Carmeliet P, (2003): VEGF and PlGF, two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 314: 5-14. (Pubitemid 37409908)
31. Wang F, Yamauchi M, Muramatsu M, et al., (2011): RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway. J Biol Chem 286: 9097-9106.
32. Werle M, &, Bernkop-Schnürch. A, (2006): Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30: 351-367. (Pubitemid 43886897)
33. van Wijngaarden P, Coster DJ, &, Williams KA, (2005): Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293: 1509-1513. (Pubitemid 40393297)
34. Xie G, Plumb R, Su M, et al., (2008): Ultra-performance LC/TOF MS analysis of medicinal Panax herbs for metabolomic research. J Sep Sci 31: 1015-1026. (Pubitemid 351649827)
35. Xu Y, Zhao H, Zheng Y, et al., (2010): A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol Vis 16: 1982-1995.
36. Yi ZF, Cho SG, Zhao H, et al., (2009): A novel peptide from human apolipoprotein (a) inhibits angiogenesis and tumor growth by targeting c-Scr phosphorylation in VEGF-induced human umbilical endothelial cell. Int J Cancer 124: 843-852.
37. Zhang SX, &, Ma JX, (2007): Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26: 1-37. (Pubitemid 44920203)
38. Zhao H, Jin HY, Li Q, et al., (2009): Inhibition of pathologic retinal neovascularization by a small peptide derived from human apolipoprotein (a). Ivest Ophthalmol Vis Sci 50: 5384-5395.